{"id":"active-controlled-vaccine-b","_chembl":null,"modality":"Biologic","_dailymed":null,"_scrapedAt":"2026-03-28T05:49:03.011Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_claudeStub":{"ts":1779123421,"model":"claude-sonnet-4-5-20250929"},"description":"Active-controlled vaccine B is an investigational vaccine developed by Sinovac Biotech Co., Ltd, currently in Phase 1 clinical trials. Limited public information is available regarding its specific molecular target, mechanism of action, or therapeutic indication at this early stage of development.","indications":{"approved":[{"status":"investigational","condition":null,"patientPopulation":null}]},"trialDetails":[{"nctId":"NCT07492706","phase":"PHASE1","title":"Safety, Tolerability and Immunogenicity of a Maternal Respiratory Syncytial Virus (RSV) Vaccine (MKK900) in Healthy Adult Women","status":"NOT_YET_RECRUITING","sponsor":"MAXVAX Biotechnology Limited Liability Company","startDate":"2026-04-01","conditions":"Respiratory Syncytial Virus (RSV)","enrollment":120},{"nctId":"NCT05547464","phase":"PHASE1, PHASE2","title":"Safety and Immune Responses After Vaccination With Two Investigational RNA-based Vaccines Against Tuberculosis in BCG Vaccinated Volunteers","status":"ACTIVE_NOT_RECRUITING","sponsor":"BioNTech SE","startDate":"2023-07-31","conditions":"Tuberculosis","enrollment":497},{"nctId":"NCT06077656","phase":"PHASE2","title":"Dose-Ranging Study to Evaluate a 25-Valent Pneumococcal Conjugate Vaccine","status":"COMPLETED","sponsor":"Inventprise Inc.","startDate":"2023-10-25","conditions":"Pneumococcal Vaccines","enrollment":220},{"nctId":"NCT06926062","phase":"NA","title":"Interpersonal Communication Training and Vaccination Workflow Training Alone and in Combination to Improve Communication and Recommendations About HPV Vaccination in Pharmacies, IMPACT HPV Trial","status":"NOT_YET_RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2026-06-01","conditions":"Human Papillomavirus-Related Carcinoma","enrollment":1900},{"nctId":"NCT05947890","phase":"PHASE2","title":"Evaluating the Safety and Immunogenicity of MTBVAC","status":"RECRUITING","sponsor":"HIV Vaccine Trials Network","startDate":"2024-01-30","conditions":"HIV I Infection, Tuberculosis","enrollment":276},{"nctId":"NCT05894954","phase":"PHASE3","title":"Precision Medicine Approach for Early Dementia & Mild Cognitive Impairment","status":"COMPLETED","sponsor":"Alzheimer's Prevention and Reversal Project, Inc.","startDate":"2023-07-31","conditions":"Mild Cognitive Impairment, Dementia, Mild","enrollment":73},{"nctId":"NCT07280858","phase":"PHASE1, PHASE2","title":"A Phase I/II, Dose-finding Study to Assess the Safety, Reactogenicity, and Immunogenicity of a Broadly Protective Sarbecovirus Vaccine (GBP511) in Healthy Adults.","status":"RECRUITING","sponsor":"SK Bioscience Co., Ltd.","startDate":"2026-01-28","conditions":"Healthy Participants, Sarbecovirus","enrollment":368},{"nctId":"NCT07400003","phase":"PHASE1, PHASE2","title":"Study to Evaluate the Safety and Immunogenicity of a Lyophilized Herpes Zoster Virus mRNA Vaccine","status":"RECRUITING","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2026-01-06","conditions":"Herpes Zoster, mRNA Vaccine","enrollment":519},{"nctId":"NCT06071767","phase":"PHASE1, PHASE2","title":"Evaluation of Safety, Immunogenicity and Efficacy of a Triple Immune Regimen in Adults Initiated on ART During Acute HIV-1","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2024-04-01","conditions":"HIV-1-infection","enrollment":36},{"nctId":"NCT05393037","phase":"PHASE3","title":"Safety and Immunogenicity of V116 in Adults Living With Human Immunodeficiency Virus (HIV) (V116-007, STRIDE-7)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-07-13","conditions":"Pneumococcal Disease","enrollment":313},{"nctId":"NCT07354659","phase":"PHASE2","title":"Immunogenicity and Safety of SYS6017 in the Participants Aged 40 Years and Above","status":"NOT_YET_RECRUITING","sponsor":"CSPC Megalith Biopharmaceutical Co.,Ltd.","startDate":"2026-01-10","conditions":"Herpes Zoster","enrollment":800},{"nctId":"NCT07327398","phase":"PHASE2","title":"Phase Ⅱ Clinical Trial of Influenza Virus Split Vaccine for Individuals Aged 60 Years and Above","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Institute Of Biological Products","startDate":"2026-01-07","conditions":"Influenza","enrollment":1200},{"nctId":"NCT05541861","phase":"PHASE1","title":"Safety and Effects of an Investigational COVID-19 Vaccine as Booster in Healthy People","status":"COMPLETED","sponsor":"BioNTech SE","startDate":"2022-11-08","conditions":"SARS-CoV-2 Infection, COVID-19","enrollment":383},{"nctId":"NCT03891758","phase":"PHASE3","title":"Confirmatory Study of BK1310 in Healthy Infants","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2019-04-01","conditions":"Tetanus, Diphtheria, Pertussis","enrollment":267},{"nctId":"NCT05645900","phase":"PHASE3","title":"A Clinical Trial of an Quadrivalent Influenza Virus Subunit Vaccine in Chinese Children Aged 6 to 35 Months","status":"COMPLETED","sponsor":"Ab&B Bio-tech Co., Ltd.JS","startDate":"2023-02-06","conditions":"Influenza","enrollment":2772},{"nctId":"NCT07203755","phase":"PHASE1","title":"Clinical Trial of the Adsorbed Acellular Pertussis (Tricomponent) DTaP-Haemophilus Influenzae Type b (Conjugate)-ACYW135 Group Meningococcal (Conjugate) Combined Vaccine","status":"RECRUITING","sponsor":"CanSino Biologics Inc.","startDate":"2025-12-19","conditions":"Diphtheria, Tetanus and Acellular Pertussis, Epidemic Meningitis, Haemophilus Influenzae Type B Infection","enrollment":260},{"nctId":"NCT05276297","phase":"PHASE2","title":"A Study on the Safety, Efficacy and Immune Response Following Sequential Treatment With an Anti-sense Oligonucleotide Against Chronic Hepatitis B (CHB) and Chronic Hepatitis B Targeted Immunotherapy (CHB-TI) in CHB Patients Receiving Nucleos(t)Ide Analogue (NA) Therapy","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2022-03-22","conditions":"Hepatitis B, Chronic","enrollment":174},{"nctId":"NCT05827926","phase":"PHASE1, PHASE2","title":"A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy Adults","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2023-04-14","conditions":"SARS-CoV-2, Influenza","enrollment":1758},{"nctId":"NCT06680128","phase":"PHASE1, PHASE2","title":"A Study to Assess the Safety, Reactogenicity, and Immunogenicity of SK Japanese Encephalitis Messenger Ribonucleic Acid (mRNA) Vaccines (GBP560) in Healthy Adults","status":"RECRUITING","sponsor":"SK Bioscience Co., Ltd.","startDate":"2025-02-24","conditions":"Japanese Encephalitis Virus Disease","enrollment":402},{"nctId":"NCT04445064","phase":"PHASE2","title":"Activity and Safety of Peptide-based Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck.","status":"TERMINATED","sponsor":"Cliniques universitaires Saint-Luc- Université Catholique de Louvain","startDate":"2020-08-14","conditions":"Oropharynx Squamous Cell Carcinoma, Larynx Squamous Cell Carcinoma, Hypopharynx Squamous Cell Carcinoma","enrollment":17},{"nctId":"NCT07285265","phase":"PHASE1","title":"Phase I Clinical Trial of Lyophilized Herpes Zoster mRNA Vaccine in Adults Aged 40 Years or Above","status":"ACTIVE_NOT_RECRUITING","sponsor":"Suzhou Abogen Biosciences Co., Ltd.","startDate":"2025-05-27","conditions":"Varicella-zoster Virus","enrollment":180},{"nctId":"NCT07270796","phase":"PHASE1","title":"Safety and Immunogenicity Study of the DuoChol Oral Cholera Vaccine in Healthy Participants","status":"NOT_YET_RECRUITING","sponsor":"International Vaccine Institute","startDate":"2025-12","conditions":"Cholera Vaccination Reaction","enrollment":60},{"nctId":"NCT05879419","phase":"PHASE4","title":"Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Sao Paulo General Hospital","startDate":"2023-05-23","conditions":"Rheumatoid Arthritis, Spondylitis, Ankylosing, Spondyloarthritis","enrollment":2005},{"nctId":"NCT07147400","phase":"PHASE2","title":"Pfs230D1 + R21 in Matrix-M1 in African School Children and Adults","status":"RECRUITING","sponsor":"Serum Institute of India Pvt. Ltd.","startDate":"2025-08-22","conditions":"Prevention of Malaria Transmission and Clinical Malaria","enrollment":1200},{"nctId":"NCT06569823","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adults 50 Years of Age and Over","status":"RECRUITING","sponsor":"Dynavax Technologies Corporation","startDate":"2024-06-17","conditions":"Shingles, Herpes Zoster, Vaccine-Preventable Diseases","enrollment":764},{"nctId":"NCT05960097","phase":"PHASE2","title":"A Study on the Safety and Immune Response of Investigational COVID-19 mRNA Vaccines in Healthy Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2023-08-01","conditions":"SARS-CoV-2, COVID-19","enrollment":692},{"nctId":"NCT06864143","phase":"PHASE2","title":"A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ≥18 to <65 Years of Age","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2025-03-07","conditions":"Influenza, SARS-CoV-2","enrollment":1320},{"nctId":"NCT07205796","phase":"PHASE2","title":"A Phase 2 Study to Describe the Safety, Reactogenicity, and Immunogenicity of Herpes Zoster IN001 mRNA Vaccine (IN001) in Healthy Participants","status":"NOT_YET_RECRUITING","sponsor":"Shenzhen Shenxin Biotechnology Co., Ltd","startDate":"2026-05-01","conditions":"Herpes Zoster","enrollment":480},{"nctId":"NCT05472038","phase":"PHASE2, PHASE3","title":"A Study to Learn About New COVID-19 RNA Vaccine Candidates in COVID-19 Vaccine-Experienced Healthy Individuals","status":"COMPLETED","sponsor":"BioNTech SE","startDate":"2022-07-26","conditions":"SARS-CoV-2 Infection, COVID-19","enrollment":1453},{"nctId":"NCT06484335","phase":"PHASE1","title":"RV630 - Approach to Control HIV With Immune Enhancement and Vaccination (ACHIEV","status":"RECRUITING","sponsor":"Henry M. Jackson Foundation for the Advancement of Military Medicine","startDate":"2025-03-27","conditions":"HIV Infections, PLWH, ART","enrollment":48},{"nctId":"NCT05782179","phase":"PHASE1","title":"Study to Evaluate the Safety, Tolerability and Immunogenicity of Three Doses of GBS Vaccine in Elderly Participants","status":"COMPLETED","sponsor":"Minervax ApS","startDate":"2023-03-01","conditions":"Group B Streptococcal Infections","enrollment":90},{"nctId":"NCT06790290","phase":"PHASE2","title":"Phase 2 Trial to Evaluate Safety and Immunogenicity of Inventprise's (IVT) 25-valent Pneumococcal Conjugate Vaccine (IVT PCV-25) in Healthy Infants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Inventprise Inc.","startDate":"2025-01-27","conditions":"Pneumococcal Disease, Invasive","enrollment":421},{"nctId":"NCT06291857","phase":"PHASE3","title":"A Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine and Influenza Combination Vaccine","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novavax","startDate":"2024-12-09","conditions":"COVID-19","enrollment":9320},{"nctId":"NCT06947499","phase":"PHASE2, PHASE3","title":"A Phase II/III Study to Evaluate the Immunogenicity, Safety and Lot-to-lot Consistency of LBVD, a Fully Liquid Hexavalent Diphtheria-tetanus-whole Cell Pertussis-hepatitis B-poliovirus-Haemophilus Influenzae Type b Conjugate (DTwP-HepB-IPV-Hib) Vaccine, in Healthy Infants as Primary Series","status":"RECRUITING","sponsor":"LG Chem","startDate":"2025-05-30","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":1186},{"nctId":"NCT04228783","phase":"PHASE3","title":"A Study of 2-dose Vaccine Regimen Using 3 Consecutive Lots of Ad26.ZEBOV and MVA-BN-Filo in Adult Participants","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2020-02-18","conditions":"Ebola","enrollment":974},{"nctId":"NCT06033261","phase":"PHASE1, PHASE2","title":"A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2023-09-06","conditions":"Genital Herpes","enrollment":365},{"nctId":"NCT06954818","phase":"PHASE1","title":"Safety and Immunogenicity of SYS6017 in Healthy Participants Aged 40 Years or More","status":"NOT_YET_RECRUITING","sponsor":"CSPC Megalith Biopharmaceutical Co.,Ltd.","startDate":"2025-05-10","conditions":"Herpes Zoster","enrollment":200},{"nctId":"NCT06955728","phase":"PHASE4","title":"A Clinical Trial on Safety in Pregnant Women and How Well the Infant is Protected Against RSV-associated Lower Respiratory Tract Infection When the Pregnant Woman Receives the Approved RSV Vaccine Compared to a Placebo.","status":"NOT_YET_RECRUITING","sponsor":"University of Witwatersrand, South Africa","startDate":"2025-05-01","conditions":"RSV Infections, RSV Immunisation, Preterm Labour","enrollment":13000},{"nctId":"NCT03566940","phase":"PHASE2","title":"A Study to Assess the Safety, Reactogenicity and Immunogenicity of a Trivalent Inactivated Poliovirus Vaccine (IPV) Based on Sabin Strains Compared to Conventional Salk IPV in a 6, 10 and 14 Weeks of Age Immunization Schedule","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2018-07-31","conditions":"Healthy","enrollment":302},{"nctId":"NCT06800131","phase":"PHASE1","title":"Hepatitis B Vaccine Delivered Trans-dermally by MAP","status":"NOT_YET_RECRUITING","sponsor":"International Vaccine Institute","startDate":"2025-02-05","conditions":"Hepatitis B Vaccine","enrollment":40},{"nctId":"NCT05603052","phase":"PHASE3","title":"A Phase III of COVID-19 Vaccine EuCorVac-19 in Healthy Adults Aged 18 Years and Older","status":"COMPLETED","sponsor":"EuBiologics Co.,Ltd","startDate":"2022-07-11","conditions":"COVID-19","enrollment":2852},{"nctId":"NCT05868382","phase":"PHASE2","title":"Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2023-05-15","conditions":"Influenza","enrollment":270},{"nctId":"NCT02868970","phase":"PHASE4","title":"Pharmacists as Immunizers to Improve Coverage and Provider/Recipient Satisfaction","status":"COMPLETED","sponsor":"Canadian Immunization Research Network","startDate":"2017-02-15","conditions":"Healthy","enrollment":2404},{"nctId":"NCT02942277","phase":"PHASE1","title":"Safety and Immunogenicity of Pfs25M-EPA/AS01 and Pfs230D1M-EPA/AS01 Vaccines, Transmission Blocking Vaccines Against Plasmodium Falciparum, at Full and Fractional Dosing in Adults in Mali","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2016-10-21","conditions":"Malaria","enrollment":301},{"nctId":"NCT05993325","phase":"PHASE3","title":"Immunogenicity and Safety of AdCLD-CoV19-1 OMI As a Booster: a COVID-19 Preventive Vaccine in Healthy Volunteers","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cellid Co., Ltd.","startDate":"2023-11-27","conditions":"COVID-19, Vaccines","enrollment":4000},{"nctId":"NCT05978037","phase":"PHASE1, PHASE2","title":"A Study to Assess the Safety and Effectiveness of Two Experimental Malaria Vaccines","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Oxford","startDate":"2023-08-18","conditions":"Malaria, Malaria,Falciparum, Parasitic Disease","enrollment":58},{"nctId":"NCT03501992","phase":"NA","title":"Multilevel Interventions to Enhance Provider Recommendations for HPV Vaccination","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2018-04-01","conditions":"Papillomavirus Vaccines","enrollment":9242},{"nctId":"NCT03537508","phase":"PHASE3","title":"Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-04-25","conditions":"Healthy Volunteers (Meningococcal Infection)","enrollment":2627},{"nctId":"NCT06413121","phase":"PHASE3","title":"Clinical Study to Assess the Immunogenicity and Safety of Hexavalent Vaccine Containing Reduced Dose IPV","status":"RECRUITING","sponsor":"Serum Institute of India Pvt. Ltd.","startDate":"2024-05-06","conditions":"Diptheria Immunization, Tetanus Immunization, Pertussis Immunization","enrollment":1557},{"nctId":"NCT05249829","phase":"PHASE2, PHASE3","title":"A Study to Evaluate the Immunogenicity and Safety of Omicron Variant Vaccines in Comparison With mRNA-1273 Booster Vaccine for COVID-19","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2022-02-16","conditions":"SARS-CoV-2","enrollment":3548},{"nctId":"NCT05572879","phase":"PHASE3","title":"A Phase III Study of COVID-19 Vaccine EuCorVac-19 in Healthy Adults","status":"COMPLETED","sponsor":"EuBiologics Co.,Ltd","startDate":"2022-10-01","conditions":"COVID-19","enrollment":2600},{"nctId":"NCT05769569","phase":"PHASE1","title":"Safety and Efficacy of Neutralizing Antibodies and Vaccination for Induction of HIV Remission","status":"WITHDRAWN","sponsor":"Henry M. Jackson Foundation for the Advancement of Military Medicine","startDate":"2023-09-01","conditions":"HIV-1-infection","enrollment":""},{"nctId":"NCT06344065","phase":"PHASE3","title":"Immunogenicity and Safety of Diphtheria, Tetanus, Pertussis (DTaP) Vaccine in 3-month-old Infants","status":"RECRUITING","sponsor":"Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd","startDate":"2023-12-21","conditions":"Healthy Volunteers","enrollment":1584},{"nctId":"NCT02605538","phase":"NA","title":"Hepatitis B in Cystic Fibrosis and Latent Tuberculosis Respectively","status":"WITHDRAWN","sponsor":"Karolinska University Hospital","startDate":"2015-09-01","conditions":"Cystic Fibrosis, Hepatitis A, Hepatitis B","enrollment":""},{"nctId":"NCT05642078","phase":"PHASE3","title":"Phase Ⅲ Clinical Study of Quadrivalent Influenza Virus Split Vaccine","status":"COMPLETED","sponsor":"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.","startDate":"2023-02-18","conditions":"Prevention of Influenza","enrollment":2550},{"nctId":"NCT06184542","phase":"PHASE1","title":"Phase I Clinical Trial of Diphtheria-Tetanus-acellular Pertussis Component Combined Vaccine","status":"RECRUITING","sponsor":"Institute of Medical Biology, Chinese Academy of Medical Sciences","startDate":"2023-12-23","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":460},{"nctId":"NCT05163561","phase":"PHASE3","title":"Evaluation of Safety and Immunogenicity of Inactivated Adjuvanted Polio Vaccine in Comparison With Licensed Inactivated Poliovirus Vaccine","status":"COMPLETED","sponsor":"Serum Institute of India Pvt. Ltd.","startDate":"2022-01-09","conditions":"Poliomyelitis","enrollment":1072},{"nctId":"NCT02677493","phase":"PHASE3","title":"Study to Evaluate the Immunogenicity and Safety of 'IL-YANG Quadrivalent Influenza Vaccine Inj.'","status":"COMPLETED","sponsor":"Il-Yang Pharm. Co., Ltd.","startDate":"2015-10","conditions":"Influenza","enrollment":1794},{"nctId":"NCT03135834","phase":"PHASE3","title":"A Trial to Describe the Immunogenicity and Safety of 2 Doses of Bivalent rLP2086 (Trumenba) and a Pentavalent Meningococcal Vaccine in Healthy Subjects >=10 to <26 Years of Age.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2017-04-24","conditions":"Meningococcal Vaccine","enrollment":1610},{"nctId":"NCT05952596","phase":"PHASE1","title":"A Study to Evaluate Safety and Immunogenicity of APV006 in Healthy Adults","status":"UNKNOWN","sponsor":"LG Chem","startDate":"2023-07-17","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":42},{"nctId":"NCT04440163","phase":"PHASE3","title":"MenABCWY Noninferiority Study in Healthy Participants ≥10 to <26 Years of Age","status":"COMPLETED","sponsor":"Pfizer","startDate":"2020-06-17","conditions":"Meningococcal Vaccine","enrollment":2431},{"nctId":"NCT05457946","phase":"PHASE2, PHASE3","title":"Study to Evaluate the Immunogenicity and Safety of LBVD(Hexavalent Vaccine), Given to Healthy Infants at Primary Series","status":"UNKNOWN","sponsor":"LG Chem","startDate":"2023-04-01","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":1438},{"nctId":"NCT05228613","phase":"PHASE1","title":"Safety and Immunogenicity Study of COVID-19 Protein Subunit Recombinant Vaccine Adjuvanted With Alum+CpG 1018","status":"COMPLETED","sponsor":"PT Bio Farma","startDate":"2022-02-16","conditions":"COVID-19","enrollment":175},{"nctId":"NCT05481801","phase":"","title":"Adherence to Guidelines VAccination in Type 1 DIabetes Mellitus Patients (AVADI-2)","status":"COMPLETED","sponsor":"Castilla-La Mancha Health Service","startDate":"2022-09-01","conditions":"Type 1 Diabetes","enrollment":300},{"nctId":"NCT03885934","phase":"PHASE3","title":"Safety and Immunogenicity of Catch-up Vaccination Regimens of V114 (V114-024)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-06-25","conditions":"Pneumococcal Infections","enrollment":606},{"nctId":"NCT03293498","phase":"PHASE1, PHASE2","title":"Evaluation of the Safety and Immunogenicity of a Recombinant Trivalent Nanoparticle Influenza Vaccine With Matrix M-1 Adjuvant (NanoFlu)","status":"COMPLETED","sponsor":"Novavax","startDate":"2017-09-18","conditions":"Influenza","enrollment":330},{"nctId":"NCT04001322","phase":"NA","title":"Tunatar da ni. The Immunization Reminder and Information SMS System (IRISS)","status":"COMPLETED","sponsor":"Johns Hopkins Bloomberg School of Public Health","startDate":"2019-06-15","conditions":"Low Immunization Uptake","enrollment":21},{"nctId":"NCT03373656","phase":"NA","title":"Vaccination for Children of H&O and Their Parents","status":"UNKNOWN","sponsor":"Children's Cancer Group, China","startDate":"2017-05-01","conditions":"Vaccination, Hematologic Malignancy, Solid Tumor, Childhood","enrollment":300},{"nctId":"NCT04966871","phase":"PHASE1","title":"Safety, Tolerability and Efficacy of PfSPZ Vaccine Against Heterologous CHMI in US Malaria naïve Adults","status":"COMPLETED","sponsor":"Sanaria Inc.","startDate":"2021-09-27","conditions":"Malaria","enrollment":54},{"nctId":"NCT00270205","phase":"PHASE1, PHASE2","title":"Safety, Tolerability and Immune Response to LC002, an Experimental Therapeutic Vaccine, in Adults Receiving HAART","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2006-01","conditions":"HIV Infections","enrollment":28},{"nctId":"NCT00000943","phase":"NA","title":"A Study to Test If Giving Remune (an HIV Vaccine) Can Improve the Immune Systems of HIV-Positive Patients Who Are Also Participating in ACTG 328","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":50},{"nctId":"NCT03491553","phase":"PHASE2","title":"Safety, Tolerability and Antiviral Activity of Selgantolimod in Virally-Suppressed Participants With Chronic Hepatitis B","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2018-04-06","conditions":"Chronic Hepatitis B","enrollment":48},{"nctId":"NCT03408730","phase":"PHASE3","title":"Lot-to-lot Consistency of Sci-B-Vac™ in Adults","status":"COMPLETED","sponsor":"VBI Vaccines Inc.","startDate":"2017-12-14","conditions":"Hepatitis B Vaccines","enrollment":2838},{"nctId":"NCT03478254","phase":"","title":"Adherence to Guidelines VAccination in Type 1 DIabetes Mellitus Patients (AVADI-1).","status":"COMPLETED","sponsor":"Jesús Moreno Fernández","startDate":"2017-12-01","conditions":"Type 1 Diabetes Mellitus","enrollment":300},{"nctId":"NCT04537130","phase":"PHASE1","title":"Vaccination of Ex-acute COVID-19 Patients With Fibrosing Lung Syndrome at Discharge","status":"UNKNOWN","sponsor":"Instituto Oncológico Dr Rosell","startDate":"2020-12-01","conditions":"Pulmonary Fibrosis, Covid19","enrollment":40},{"nctId":"NCT00492739","phase":"PHASE2, PHASE3","title":"Immunity Against Varicella in Pediatric Orthotopic Liver Transplantation Recipients","status":"UNKNOWN","sponsor":"University Hospital, Geneva","startDate":"2007-06","conditions":"Liver Disease, Immunosuppression, Varicella","enrollment":80},{"nctId":"NCT03058692","phase":"PHASE2","title":"Two Doses of Multimeric-001 (M-001) Followed by Influenza Vaccine","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2018-04-09","conditions":"Influenza, Influenza Immunisation","enrollment":120},{"nctId":"NCT03933098","phase":"PHASE3","title":"Immune Non-inferiority and Safety of a Vi-DT Typhoid Conjugate Vaccine","status":"UNKNOWN","sponsor":"International Vaccine Institute","startDate":"2019-11-15","conditions":"Typhoid","enrollment":1800},{"nctId":"NCT03797950","phase":"NA","title":"Mobile Nudges to Increase Early Vaccination Coverage in Rural Areas","status":"COMPLETED","sponsor":"Swiss Tropical & Public Health Institute","startDate":"2018-11-01","conditions":"Immunization Coverage","enrollment":260},{"nctId":"NCT02431312","phase":"PHASE1","title":"Phase I Study of INO-1800 With or Without INO-9112 + EP in Chronic Hepatitis B Subjects","status":"COMPLETED","sponsor":"Inovio Pharmaceuticals","startDate":"2015-01-12","conditions":"Hepatitis B","enrollment":90},{"nctId":"NCT02097472","phase":"PHASE1, PHASE2","title":"Dose-Finding Study of S.Pneumoniae Whole Cell Vaccine Adsorbed to Alum (PATH-wSP) in Healthy Kenyan Adults and Toddlers","status":"COMPLETED","sponsor":"PATH","startDate":"2014-04","conditions":"Pneumonia, Pneumococcal","enrollment":304},{"nctId":"NCT04073459","phase":"PHASE2","title":"Safety and Immunogenicity of Hexavalent Vaccine(DTwP-HepB-IPV-Hib) in Healthy Infants","status":"UNKNOWN","sponsor":"LG Chem","startDate":"2019-11","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":336},{"nctId":"NCT03169725","phase":"PHASE2, PHASE3","title":"A Clinical Study to Evaluate the Safety and Immunogenicity of Inactivated Poliomyelitis Vaccine in Healthy Infants","status":"COMPLETED","sponsor":"LG Chem","startDate":"2017-05-31","conditions":"Poliomyelitis","enrollment":1417},{"nctId":"NCT03208101","phase":"PHASE1","title":"A Study to Compare LBVD to Eupenta and Imovax Polio in Healthy Adults","status":"COMPLETED","sponsor":"LG Chem","startDate":"2017-07-03","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":42},{"nctId":"NCT02109354","phase":"PHASE1","title":"Safety of and Immune Response to Vaccination With 2 Experimental HIV Vaccines in Healthy Adults","status":"COMPLETED","sponsor":"HIV Vaccine Trials Network","startDate":"2013-06-18","conditions":"HIV Infection","enrollment":202},{"nctId":"NCT01489020","phase":"PHASE1","title":"Subcutaneous Immunotherapy in Patients Sensitized to Dermatophagoides Pteronyssinus (DPT)","status":"COMPLETED","sponsor":"Roxall Medicina España S.A","startDate":"2011-01","conditions":"Allergic Rhinoconjunctivitis","enrollment":48},{"nctId":"NCT01341639","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 3, 4 and 12 Months (V419-007)","status":"COMPLETED","sponsor":"MCM Vaccines B.V.","startDate":"2011-05-26","conditions":"Bacterial Infections, Virus Diseases","enrollment":1250},{"nctId":"NCT01480258","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 11 to 12 Months (V419-008)","status":"COMPLETED","sponsor":"MCM Vaccines B.V.","startDate":"2011-11-23","conditions":"Bacterial Infections, Virus Diseases","enrollment":1315},{"nctId":"NCT02117934","phase":"PHASE3","title":"Safety and Immunogenicity Study of the Hepatitis B Vaccine, HEPLISAV™, Compared to Engerix-B® Vaccine","status":"COMPLETED","sponsor":"Dynavax Technologies Corporation","startDate":"2014-04","conditions":"Healthy","enrollment":8374},{"nctId":"NCT01461980","phase":"PHASE2","title":"A Clinical Trial to Study the Safety, Tolerance and Immunogenic Response to MCV4, Tdap and Bivalent rLP2086 Vaccine When Given at the Same Time to Children Between the Ages of 10 Through 12 Years of Age","status":"COMPLETED","sponsor":"Pfizer","startDate":"2011-09-28","conditions":"Vaccines, Meningococcal Vaccines","enrollment":2648},{"nctId":"NCT01461993","phase":"PHASE2","title":"A Clinical Trial to Study the Safety, Tolerance and Immunogenic Response to Gardasil and Bivalent rLP2086 Vaccine When Given at the Same Time to Children Between the Ages of 11 and 17","status":"COMPLETED","sponsor":"Pfizer","startDate":"2011-09-28","conditions":"Vaccines, Meningococcal Vaccines","enrollment":2499},{"nctId":"NCT01340937","phase":"PHASE3","title":"A Study of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-006)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-05-10","conditions":"Bacterial Infections, Virus Diseases","enrollment":2808},{"nctId":"NCT01337167","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-005)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-04-19","conditions":"Bacterial Infections, Virus Diseases","enrollment":1473},{"nctId":"NCT02446743","phase":"PHASE3","title":"Combined Study - Phase 3b MenB Long Term Persistence in Adolescents","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-11-17","conditions":"Infections, Meningococcal","enrollment":531},{"nctId":"NCT00510874","phase":"PHASE1","title":"Study to Evaluate the Safety and Immune Response of Two-Doses of Candidate Influenza Vaccine GSK 1557484A in Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-07-28","conditions":"Influenza","enrollment":780},{"nctId":"NCT00952705","phase":"PHASE3","title":"A Study to Evaluate the Immunogenicity of Quadrivalent LAIV (MEDI8662) in Adults 18 to 49 Years of Age","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2009-08","conditions":"Healthy or Stable Underlying Chronic Medical Condition","enrollment":1800},{"nctId":"NCT02691130","phase":"PHASE2","title":"Assess the Safety and Immunogenicity of M-001 as A Standalone Influenza Vaccine and as A H5N1 Vaccine Primer in Adults","status":"COMPLETED","sponsor":"BiondVax Pharmaceuticals ltd.","startDate":"2015-11","conditions":"Influenza, Healthy","enrollment":224},{"nctId":"NCT01150123","phase":"PHASE1","title":"Safety and Immunogenicity of a Group B Streptococcus Vaccine in Healthy Women","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2010-05","conditions":"Group B Streptococcus","enrollment":678},{"nctId":"NCT01704781","phase":"PHASE1, PHASE2","title":"Vacc-4x + Lenalidomide vs. Vacc-4x +Placebo in HIV-1-infected Subjects on Antiretroviral Therapy (ART)","status":"COMPLETED","sponsor":"Bionor Immuno AS","startDate":"2012-09","conditions":"HIV-1 Infection","enrollment":36},{"nctId":"NCT01518478","phase":"EARLY_PHASE1","title":"Atopic Dermatitis Research Network (ADRN) Influenza Vaccine Pilot","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2011-11","conditions":"Atopic Dermatitis","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_1","status":"active","brandName":"Active-controlled vaccine B","genericName":"Active-controlled vaccine B","companyName":"Sinovac Biotech Co., Ltd","companyId":"sinovac-biotech-co-ltd","firstApprovalDate":"","aiSummary":"Active-controlled vaccine B, also known as mRNA-1608, is being studied in clinical trials for various conditions including metastatic melanoma, genital herpes, hepatitis B, and varicella-zoster virus.","enrichmentLevel":2,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}